I-Mab (IMAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, I-Mab (IMAB) has a cash flow conversion efficiency ratio of 0.007x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.84 Million) by net assets ($258.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See I-Mab defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
I-Mab - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how I-Mab's cash flow conversion efficiency has evolved over time, based on yearly financial data.
I-Mab Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of I-Mab ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eastern & Oriental Bhd
KLSE:3417
|
-0.010x |
|
Jiangsu Skyray Instrument Co
SHE:300165
|
0.027x |
|
Xiamen Savings Environmental
SHE:300056
|
-0.102x |
|
Jinfa Labi Maternity & Baby Articles Co Ltd
SHE:002762
|
-0.014x |
|
UE Furniture Co Ltd
SHG:603600
|
0.098x |
|
Shanghai Conglin Environmental Protection Technology Co. Ltd. A
SHG:688370
|
N/A |
|
Rongfeng Holding Group
SHE:000668
|
-0.064x |
|
Fenerbahce Futbol AS
IS:FENER
|
-10.835x |
Annual Cash Flow Conversion Efficiency for I-Mab (2017–2024)
The table below shows the annual cash flow conversion efficiency of I-Mab from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see IMAB stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $201.16 Million | $-52.67 Million | -0.262x | +65.53% |
| 2023-12-31 | $1.72 Billion | $-1.30 Billion | -0.760x | -107.18% |
| 2022-12-31 | $3.01 Billion | $-1.10 Billion | -0.367x | -72.83% |
| 2021-12-31 | $4.59 Billion | $-973.09 Million | -0.212x | -375.29% |
| 2020-12-31 | $5.63 Billion | $433.56 Million | 0.077x | -81.94% |
| 2019-12-31 | $-2.03 Billion | $-867.98 Million | 0.427x | +45.15% |
| 2018-12-31 | $-955.10 Million | $-280.70 Million | 0.294x | -65.06% |
| 2017-12-31 | $-299.80 Million | $-252.16 Million | 0.841x | -- |
About I-Mab
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment o… Read more